Myeloma, MGUS & related conditions

PDF / 652KB Download Provide Feedback

Myeloma, MGUS and related conditions: A Guide for GPs

This guide is written for GPs to help in the diagnosis of myeloma and monoclonal gammopathies. Primary care clinicians play a critical role in the early diagnosis of myeloma by being able to:

  • Spot red flag symptoms of myeloma.
  • Request the relevant investigations.
  • Know when to seek advice or make a referral.
  • Manage patients with low-risk MGUS.

Created specifically for GPs, this guide includes information about myeloma and the tests required to help with diagnosis, guidance on how to interpret test results and when referral to haematology might be needed.

It was developed in partnership with a panel of expert clinicians (including GPs, haematologists, clinical scientists and immunologists) from across the UK and is designed to be used in conjunction with our GP Myeloma Diagnostic Tool.  These resources have been developed as part of the Myeloma UK ‘diagnose myeloma earlier’ strategy to speed up the detection, referral and diagnosis of myeloma.

Would you like printed copies of this resource?

Visit our order form and scroll to the Healthcare professional resources section.

Use Case

Type

Source

  • Myeloma UK

You might also like

  • GP Myeloma Diagnostic Tool (for Scotland)

    Introducing the Scottish version of the GP Myeloma Investigation Tool – a concise resource designed to support GPs in recognising the signs and symptoms of myeloma, ordering the appropriate tests, and confidently interpreting laboratory results. The tool also provides clear guidance on when and how urgently to refer patients, using NICE terminology while acknowledging regional variations in practice.

    Myeloma UK Information Guide
  • GP Myeloma Diagnostic Tool

    Early diagnosis of myeloma relies on primary care clinicians being able to accurately suspect, test and refer patients with suspected myeloma. It is important that GPs are able to distinguish those patients that require urgent investigation in secondary care versus those that likely have lower risk MGUS and so can be monitored in primary care or via discussion with a haematologist.

    Myeloma UK Information Guide